Skip navigation
Jul22

T3 Pharma raises 25M CHF to advance bacterial cancer therapy through clinic

Basel, Switzerland - July 22, 2020 - T3 Pharmaceuticals AG (“T3 Pharma”), a Swiss biotech advancing immuno-oncology with its bacteria-based protein delivery platform, today announced the closing of its third financing round, raising over 25M CHF.

The financing was co-led by existing investors, including the Boehringer Ingelheim Venture Fund (BIVF), Reference Capital SA, Wille Finance AG and private investors, who all participated in the round. This latest financing brings T3 Pharma’s total funding since the launch of the Company in 2015 to 40 million CHF.

T3 Pharma will use the funds primarily to progress its lead candidate, T3P-Y058-739, through clinical studies. The Phase 1/2 clinical study in solid tumors is planned to start in early 2021.

T3P-Y058-739 is the first therapeutic candidate developed using T3 Pharma’s proprietary protein delivery platform. The technology is built on the discovery that the bacterial type III secretion (T3S) system can be repurposed to deliver chosen proteins into eukaryotic cells.1 T3 Pharma’s live bacteria vehicles have been optimised to accumulate and grow selectively at solid tumors, where they produce and deliver the therapeutic protein.

Dr. Simon Ittig, T3 Pharma’s CEO, commented: “This significant financing round comes at a pivotal moment for our company as we leverage the full potential of our proprietary platform and enter the clinic with our lead candidate. We are grateful to our investors for their continued support.”

“Our novel approach to deliver bioactive proteins selectively to cancerous cells using live bacteria has the potential to revolutionize treatment of solid tumors,” added Dr. Olivier Valdenaire, Chairman of the Board.

Dr. Frank Kalkbrenner, Global Head of BIVF, commented: “Since I joined the Board last year, I have been impressed not only by the technology, but also by the team and the approach they have taken to building T3 Pharma’s innovative, differentiated platform and progressing its lead candidate. It is an endorsement of the quality of the science and the team that another financing round has been completed with an exceptional group of investors, which share our vision of improving the lives of cancer patients.”

References
1. Ittig SJ, et al. A bacterial type III secretion-based protein delivery tool for broad applications in cell biology. J Cell Biol, 2015; 211 (4): 913-931. https://doi.org/10.1083/jcb.201502074


Notes to editors

About T3 Pharmaceuticals AG

T3 Pharma is a biotechnology company developing bacteria-based immuno-oncology therapies to treat solid tumors. The Company has built a proprietary protein delivery platform by repurposing the bacterial type III secretion (T3S) system. Its lead product, T3P-Y058-739, is expected to enter the clinic in 2021.

T3 Pharma was founded in 2015 as a spin-off from the Biozentrum of the University of Basel. Since then, it has raised a total of 40 million CHF in funding from investors, including the Boehringer Ingelheim Venture Fund, Reference Capital SA, Wille Finance AG and private Swiss investors.

The Company was among the first to receive support from the BaseLaunch accelerator program. It has gone on to win a W.A. De Vigier Foundation Award in 2019, was named “2018 Science Start-Up of the Year” by Falling Walls Venture and came first in the Venture.ch Business Plan Competition in 2016.

For further information, please visit www.t3pharma.com, or follow us on Twitter or LinkedIn.

For more information please contact:

T3 Pharmaceuticals AG
Email: media(at)t3pharma(dot)com

Instinctif Partners (for English-speaking and International media)
Dr Christelle Kerouedan / Dr Katie Duffell
Tel: +44 (0)20 7457 2013
Email: T3-Pharma(at)instinctif(dot)com

 

 

Jul14

T3 Pharmaceuticals testimonial film from the Lichtsteiner Foundation

Basel, Switzerland - July 14 2020 - We are happy to share the testimonial film from the Lichtsteiner Foundation about T3 Pharma.

Many thanks to the Lichtsteiner Foundation (lichtsteinerfoundation.org) for their support!

Movie on Vimeo: Lichtsteiner Foundation. Testimonial: T3 Pharma​​​​​​​

 

Sep26

Closing of financing round and strengthening of development team paves the way for T3 Pharma to enter the clinic

Basel/Switzerland, September 26, 2019 – T3 Pharmaceuticals AG (T3), a Basel (Switzerland)-based company focusing on immuno-oncology, closes its second financing round of over 12M CHF with existing investors joined by «Boehringer Ingelheim Venture Fund» (BIVF) and «Reference Capital SA». To progress into the clinical phase, T3 appoints Claire Barton as Chief Medical Officer, strengthens its development team and announces the clinical advisory board.

«We are very pleased to be joined by two experienced and specialised investors, the Boehringer Ingelheim Venture Fund and Reference Capital SA. This is optimal for completing preclinical work, and for planning and conducting the clinical trials ahead of us» comments Simon Ittig, CEO of T3. «The support of these investors validates our work and indicates that we are on the right track. This strong setup allows us to keep focusing on our core business. Special thanks are due to our existing investors who have supported us since inception». With the addition of these two new investors, T3 has now closed its second financing round with over 12M CHF.

Collaboration with investors, a dedicated team and continued support from the Biozentrum of the University of Basel provide an excellent position for T3 to complete preclinical activities for its lead candidate, which originated from the T3 platform. T3 is developing a proprietary protein delivery technology based on live bacteria expressing the «type 3 secretion system». The company has engineered the bacteria to grow selectively within solid tumors where they produce and deliver therapeutic proteins. T3’s lead product, called T3P-Y058-739, is expected to enter clinical testing in the middle of 2020.

Dr. Frank Kalkbrenner joins board of directors
To benefit from the expertise and strategic skills of the new investors, T3 welcomes Dr. Frank Kalkbrenner, managing director of BIVF, to its board of directors. «It was not only the technology and data, but the strategy and the team of T3 that convinced us to join» says Frank Kalkbrenner.

Nomination of Chief Medical Officer, strengthening of development team and formation of clinical advisory board
Joined by two experienced drug developers, T3 gains the knowhow needed to accurately plan and conduct its clinical trials. «I am looking forward to testing this exciting and innovative approach with T3», adds Dr. Claire Barton, the newly nominated Chief Medical Officer. Claire has been supporting the company for the last 18 months as a consultant.

For clinical operations, T3 is further supported by Dr. Gabriella Galli, who joins T3 from Amgen where she was responsible for clinical trials with the oncolytic virus T-Vec.

T3 also announces its clinical advisory board, composed of Prof. Kevin Harrington (Royal Marsden Hospital, London), Prof. Reinhard Dummer (University Hospital Zürich), Prof. George Coukos and Dr. Stefan Zimmermann (both from CHUV Lausanne), and Prof. Aurélien Marabelle (Gustave Roussy, Paris). «I am delighted to have this opportunity to assist in the clinical development of T3 in concert with a highly distinguished group of clinician scientists» comments Kevin Harrington, «The T3 treatment platform has a huge degree of novelty and the potential to be applicable across a broad range of cancer types».


About T3 Pharmaceuticals AG
T3 was founded in May 2015 as a spin-off of the University of Basel, Switzerland. The Company is focusing on immuno-oncology (bacteria-based) therapies for the treatment of solid tumors. Cancer immunotherapy is seen as a turning point in the fight against cancer. Unlike traditional therapies that attack the tumor directly, the goal of immunotherapies is to stimulate the immune system to selectively recognize and attack tumor cells. T3 is among the first companies supported by BaseLaunch. It was awarded «Science Startup of the year 2018» at Falling Walls Venture, won the Venture.ch business plan competition in 2016 and recently the W.A. de Vigier Award.

For further information, contact:
Dr. Simon Ittig, CEO
Phone: +41 61 207 22 00
Email: media(at)t3pharma(dot)com

Boehringer Ingelheim Venture Fund
Created in 2010, the Boehringer Ingelheim Venture Fund GmbH (BIVF) invests in groundbreaking therapeutics-focused biotechnology companies to drive innovation in biomedical research. BIVF is searching for significant enhancements in patient care through pioneering science and its clinical translation by building long-term relationships with scientists and entrepreneurs. BIVF’s focus is to target unprecedented therapeutic concepts addressing high medical needs in immuno-oncology, regenerative medicine, infectious diseases and digital health. These may include novel platform technologies to address so far undruggable targets, new generation vaccines and/or new biological entities, such as oncolytic virotherapy.
BIVF takes an active role with its portfolio companies – delivering significant added value through its own extensive drug discovery, scientific and managerial expertise. BIVF has EUR 250 million under management and currently supervises a portfolio of more than 25 companies. For more information, please visit: www.boehringer-ingelheim-venture.com

Reference Capital
As the oldest firm dedicated to private investments in Switzerland, Reference Capital SA (formerly Genevest SA) has backed outstanding companies in tech, biotech and medtech since 1983. Reference Capital’s team and network of experts span 3 continents. They provide access, expertise, and protection of interests to a select number of family offices and long-term investors seeking superior returns and investments with purpose. Reference Capital’s new investment programme, launched in 2019, connects investors to a curated and tailor-made portfolio of Private Equity and Venture Capital Funds as well as direct investments, shaping the future of the life sciences and technology sectors. Reference Capital’s direct-early stage investments with successful exits include Swiss life sciences companies, such as Actelion, Axovan, Endoart, Kuros, Neocutis, Novimmune and Thommen Medical.

Chief Medical Officer Dr. Claire Barton
Dr. Claire Barton is a medical oncologist/pharmaceutical physician specializing in the clinical development of products for oncology indications. Dr. Barton has experience in all aspects of the planning, running, reporting, and publication of clinical trials (phase I-IV) in diverse areas of oncology. She served the pharmaceutical industry in positions at GlaxoWellcome, Lilly, and Roche, and has served as a consultant to a range of smaller companies and academic groups.

May28

T3 Pharmaceuticals wins highest endowed award for startup companies in Switzerland

Basel/Switzerland, May 28, 2019 – T3 Pharmaceuticals AG – a biotech company in Basel focused on immunooncology – wins the W.A. de Vigier Foundation’s highest endowed award for startup companies in Switzerland with CHF 100,000 in prize money.

«We are honored to receive the W.A. de Vigier Foundation’s oldest and highest endowed sponsorship award and would like to thank the foundation and foundation board for recognizing the potential of our immuno-oncology approach. Our thanks also go to the University of Basel, our partners and supporters and, particularly to our investors, with whom we have joined forces to move this project ahead. A special gratitude goes to the Grisard family, who donated our price», commented Simon Ittig, CEO of T3 Pharma. At yesterday’s award ceremony in Solothurn, the Foundation awarded ten prizes in total: five prizes of CHF 100 000 and five prizes of CHF 50 000. Five winning companies were awarded from a record number of 256 applications in a multi-step selection process  – T3 Pharma was one of those top five startup companies.

For three decades, the W.A. de Vigier Foundation has awarded the highest endowed startup prize in Switzerland, independently and with no strings attached. The Foundation places particular importance on the entrepreneur’s personality. In addition, the following aspects are relevant for the evaluation: the degree of innovation, the value for society as a whole, the technical and financial viability, market prospects and the potential for job creation.

The targeted Cancer Therapy using bacteria of T3 Pharmaceuticals was convincing. Cancer immunotherapy is seen as a turning point in the fight against cancer: Unlike traditional therapies that attack the tumor directly, T3 Pharma’s immunotherapy stimulates the immune system to selectively recognize and attack tumor cells. «Our bacteria provide a powerful and versatile platform» says Christoph Kasper, CSO of T3 Pharma. «The collected results confirm the medical potential of our immuno-oncological therapy. Work to complete the preclinical package for the lead candidate is well advanced and preparations for clinical development have been initiated», adds Simon Ittig, CEO of T3 Pharma, who convinced the jury not only with his idea but also with his spirit.


About T3 Pharma
T3 Pharmaceuticals was founded in May 2015 as a spin-off of the Biozentrum, University of Basel, Switzerland. The Company focuses on bacteria-based immuno-oncology therapies for the treatment of solid tumors. T3 Pharma has been selected as “Science Startup of the year 2018” at Falling Walls Venture, has been among the first BaseLaunch companies and was awarded top1 at the Venture.ch business plan competition in 2016.

For further information, please contact:
Dr. Simon Ittig, CEO
Phone: +41 61 207 22 00
Email: media@t3pharma.com

Nov09

T3 Pharma wins prestigious Falling Walls Venture Award for its bacterial cancer therapy

Basel/Switzerland, November 9, 2018 – T3 Pharmaceuticals (“T3 Pharma”), a biotech company with a focus on immuno-oncology, today announced it has been named “2018 Science Start-Up of the Year” by Falling Walls Venture. The award honors emerging scientist-entrepreneurs for their breakthrough business models.

The Falling Walls Conference in Berlin, Germany, annually invites the world’s leading scientists to identify trends, opportunities and solutions for global challenges and discover international breakthrough research. Falling Walls Venture showcases the most promising research based start-ups from all over the globe that tear down walls and overcome boundaries in their respective fields.

“We are honored to receive this prestigious award. We thank the jury for recognizing the medical potential of our immuno-oncology approach. Our sincerest thanks go to all our friends, partners and supporters and, particularly, to the University of Basel, who nominated us for this award”, commented Dr. Simon Ittig, CEO of T3 Pharma. “The Falling Walls Venture Award confirms our aspirations to advance our therapy into clinical use for the benefit of cancer patients.”

T3 Pharma’s engineered bacteria stimulate the immune system by delivering selected human proteins directly into cells of the tumor microenvironment. Preclinical studies in a number of tumor models demonstrated a strong impact on tumor progression as well as a durable immune-mediated memory to fight recurring tumors. The clinical development for the lead candidate has been initiated in order to assess the immunotherapy in men with a first clinical trial anticipated for the first half of 2020.


For further information, contact
Dr. Simon Ittig, CEO
Phone: +41 61 207 22 00
Email: media@t3pharma.com

About T3 Pharma
T3 Pharmaceuticals was founded in May 2015 as a spin-off of the University of Basel, Switzerland. The company is focusing on bacteria-based therapies for the treatment of solid tumors. For further information, please visit www.t3pharma.com.

Jan30

T3 Pharma selected for second stage of BaseLaunch accelerator program

Basel/Switzerland, January 30, 2018 – T3 Pharmaceuticals Ltd (“T3 Pharma”), a Swiss-based biotechnology company specializing in breakthrough bacteria-based cancer therapies, today announced its selection for the second stage of BaseLaunch’s accelerator program. T3 Pharma is one of six companies that qualified for this next phase. In addition to industry access and expert knowledge, T3 Pharma receives a non-dilutive funding to support its scientific research until the next value inflection milestone.

BaseLaunch is an accelerator program for promising and innovative healthcare startups benefiting from the dynamic life sciences cluster of the Basel region. The entrepreneurial-centric accelerator program offers non-dilutive funding, industry access, expert knowledge and infrastructure. BaseLaunch is backed by leading industry players Johnson & Johnson Innovation, Novartis Venture Fund, Pfizer, Roche and Roivant Sciences. The mission of BaseLaunch is to support healthcare entrepreneurs and integrate them into one of the most dynamic biotech and pharma ecosystems in Europe.

 “In Phase I, we provided a highly customized program making the needs of the entrepreneurs and their ventures our key priorities,” said Alethia de León, Managing Director of BaseLaunch. “In Phase II, we will help the selected companies to move further in the venture creation process and to attract further investments.” Out of originally 112 applicants, eleven candidates were selected for the first phase of the accelerator program and six of them for the second phase. T3 Pharma will be one out of four companies that will receive non-dilutive funding in Phase II.

“We are proud to be among the companies that qualified for the second stage of BaseLaunch’s accelerator program”, said Dr. Simon Ittig, CEO and co-founder of T3 Pharma. “T3 Pharma will benefit from access to valuable industry and market knowledge as well as BaseLaunch’s extensive network. The selection for the second stage underlines the strong scientific and medical potential of our technology.”


For further information, contact
Dr. Simon Ittig, CEO
Phone: +41 61 207 22 00
Email: media@t3pharma.com

About T3 Pharma
The vision of T3 Pharmaceuticals Ltd is to improve the lives of cancer patients by developing very specific and efficient therapies using live bacteria. The Company was founded in May 2015 as a spin-off of the University of Basel. T3 Pharma is developing an efficient protein delivery technology that is based on the use of live bacteria expressing the type 3 secretion system. While the technology has a wide spectrum of applications in drug development, T3 Pharma has been advancing the platform as a novel therapeutic approach to treat solid tumors.

Jan16

T3 Pharma research project receives support by the Gebert Rüf Stiftung

Basel/Switzerland, January 16, 2017 – The Gebert Rüf Stiftung has announced the winners of the call 2016 «Microbials – Direct Use of Micro-Organisms». Amongst the supported projects is T3 Pharma’s innovative bacteria-based cancer therapy. The applied research project takes place at the University of Basel, the results will allow T3 Pharma to expand its activities in the field of cancer treatment using live bacteria.

With the call «Microbials – Direct Use of Micro-Organisms», held for the first time, the Gebert Rüf Stiftung seeks to jumpstart the direct use of modified or domesticated micro-organisms in human and veterinary medicine as well as other areas. Out of 54 submissions 5 projects were selected for funding. «Microbial Treatment of Solid Tumors», a collaborative effort between the Biozentrum and the Department Biomedicine of the University of Basel and T3 Pharma, is amongst the selected projects and will receive CHF 400’000 in the next two years.

“Our bacteria-based therapies hold great potential for the treatment of solid tumors and it is our aim to broadly exploit this innovative platform”, said Dr. Simon Ittig, CEO of T3 Pharma. “We are very pleased that the Gebert Rüf Stiftung shares this vision and are convinced that its support will help to significantly advance the project.”


For further information, contact
Dr. Simon Ittig, CEO
Phone: +41 61 207 22 00
Email: media@t3pharma.com

About T3 Pharma
The vision of T3 Pharmaceuticals Ltd is to improve the lives of cancer patients by developing very specific and efficient therapies using live bacteria. The Company was founded in May 2015 as a spin-off of the University of Basel. T3 Pharma is developing an efficient protein delivery technology that is based on the use of live bacteria expressing the type 3 secretion system. While the technology has a wide spectrum of applications in drug development, T3 Pharma has been advancing the platform as a novel therapeutic approach to treat solid tumors.

About Gebert Rüf Stiftung
Gebert Rüf Stiftung was established as a scientific foundation in 1997 by the entrepreneur Heinrich Gebert. The purpose of the Foundation is to strengthen Switzerland as a business location and place to live in through the promotion of scientific projects at Swiss institutions of higher education. These can be projects in all disciplines, provided they exhibit a high degree of originality, foster intellectual and practical stimulus and thus promise to be of material or immaterial benefit to society. As a private foundation with limited funds, Gebert Rüf Stiftung strives to occupy scientific niches and fill structural and procedural gaps in the world of research. For further information, please visit www.grstiftung.ch.

Nov23

T3 Pharma closes first financing round to advance research and preclinical development of breakthrough bacteria-based cancer therapies

Basel/Switzerland, November 23, 2016 – T3 Pharmaceuticals Ltd (“T3 Pharma”), a Swiss-based biotechnology company specializing in breakthrough bacteria–based cancer therapies, today announced the successful closing of its first financing round. The funding has been provided by private Swiss investors and will secure further growth of the company, in particular the expansion of research activities and the initiation of preclinical development.

The financing round complements the successful efforts raising significant non-dilutive capital from the Swiss Commission for Technology and Innovation and various research foundations. T3 Pharma is a spin-off from the Biozentrum of the University of Basel. The Company focuses on novel therapies for cancer patients. T3 Pharma has been engineering live bacteria to specifically infect solid tumors and fighting them with a proprietary protein delivery technology developed at the University of Basel.

“Our strong investor base and the support by the University of Basel provide perfect conditions for the development of our breakthrough technology in cancer therapies”, said Dr. Simon Ittig, CEO and  co-founder of T3 Pharma. “This first financing round allows us to advance initial lead candidates into preclinical development.”

“It belongs to the mission of a modern University to help translating basic research into tangible benefits for patients and society,” explained Prof. Dr. Erich Nigg, Director of the Biozentrum. “We hope that T3 Pharma can exploit their innovative platform to bring novel treatments to cancer patients.”


For further information, contact
Dr. Simon Ittig, CEO
Phone: +41 61 207 22 00
Email: media@t3pharma.com

About T3 Pharma
The vision of T3 Pharmaceuticals Ltd is to improve the lives of cancer patients by developing very specific and efficient therapies using live bacteria. The Company was founded in May 2015 as a spin-off of the University of Basel. T3 Pharma is developing an efficient protein delivery technology that is based on the use of live bacteria expressing the type 3 secretion system. While the technology has a wide spectrum of applications in drug development, T3 Pharma has been advancing the platform as a novel therapeutic approach to treat solid tumors.

Nov02

T3 Pharma has been awarded with the CTI startup label

Basel/Switzerland, November 14, 2016 – T3 Pharma has been awarded the CTI Start-up Label by the Commission for Technology and Innovation CTI.

The label is the result of a coaching process that allowed T3 Pharma to refine its corporate strategy. T3 Pharma is honored to have received the Start-up Label which is "a seal of quality, a certificate of achievement, and a sign of credibility and readiness for sustainable growth".

 

Jul01

T3 Pharma wins Venture.ch business plan competition

Basel/Switzerland, July 1, 2016 – We are happy to announce that T3 Pharma has won the venture.ch business plan competition. It’s a big honor and without the many people that support us it would not have been possible.

Thank you all!

The T3 Pharma Team

(Image: Venture 2016)

Our mission


T3 Pharmaceuticals is a pre-clinical biopharmaceutical company working to advance new generation therapies for cancer patients. Our dedicated team is developing highly specific and efficient treatments using live bacteria.